22 February 2021 in Cardiovascular Research
Aims: Angiotensin II (AngII) is a potential contributor to the development of abdominal aortic aneurysm (AAA). In aortic vascular smooth muscle cells (VSMCs), exposure to AngII induces mitochondrial fission via dynamin-related protein 1 (Drp1). However, pathophysiological relevance of mitochondrial morphology in AngII-associated AAA remains unexplored. Here, we tested the hypothesis that mitochondrial fission is involved in the development of AAA. Methods and results: Immunohistochemistry was performed on human AAA samples and revealed enhanced expression of Drp1. In C57BL6 mice treated with AngII plus β-aminopropionitrile, AAA tissue also showed an increase in Drp1 expression. A mitochondrial fission inhibitor, mdivi1, attenuated AAA size, associated aortic pathology, Drp1 protein induction, and mitochondrial fission but not hypertension in these mice. Moreover, western-blot analysis showed that induction of matrix metalloproteinase-2, which precedes the development of AAA, was blocked by mdivi1. Mdivi1 also reduced the development of AAA in apolipoprotein E-deficient mice infused with AngII. As with mdivi1, Drp1+/− mice treated with AngII plus β-aminopropionitrile showed a decrease in AAA compared to control Drp1+/+ mice. In abdominal aortic VSMCs, AngII induced phosphorylation of Drp1 and mitochondrial fission, the latter of which was attenuated with Drp1 silencing as well as mdivi1. AngII also induced vascular cell adhesion molecule-1 expression and enhanced leucocyte adhesion and mitochondrial oxygen consumption in smooth muscle cells, which were attenuated with mdivi1. Conclusion: These data indicate that Drp1 and mitochondrial fission play salient roles in AAA development, which likely involves mitochondrial dysfunction and inflammatory activation of VSMCs.
1 September 2012 in Journal Of Hypertension
1 April 2021 in Journal Of Hypertension
Objective: We recently identified the physical interaction of a pattern recognition receptor (PRR), lectin-like oxidized LDL receptor with the GPCR, angiotensin II type 1 receptor (AT1) whereby oxLDL allosterically activates AT1. In this study, we investigated if AT1 physically interacts with another PRR, the receptor for AGE (RAGE), and ligands of RAGE could allosterically activate AT1. Design and method: We used normal rat kidney epithelial cells (NRK52E) to investigate the interaction of the endogenous receptors. We also generated five different genetically-engineered CHO cells to individually analyze the G protein and .β-arrestin pathways of AT1 activation; CHO cells expressing human RAGE (CHO-RAGE), CHO cells expressing both hRAGE and hAT1 (CHO-RAGE-AT1), CHO cells expressing both hRAGE and mutated hAT1 with impaired ability to activate G protein, and CHO cells expressing both hLOX-1 and mutated hAT1 with impaired ability to activate .β-arrestin Results: In NRK52E, AGE-BSA provoked the activation of MAP kinase (ERK) that was inhibited by ARB or siRNA of AT1 or RAGE. Activation of NfκB and Epithelial mesanchmal transition induced by AGE-BSA was inhibited by ARBs as well as RAGE inhibitor. In genetically engineered CHO-cells, in situ PLA assay and immunoprecipitation confirmed the physical interaction of AT1 and RAGE on cellular membrane. HMGB1, a RAGE ligand induced Gαi-dependent inhibition of cAMP production only in the presence of both RAGE and AT1 with intact G protein binding. The effect of HMGB1 on cAMP content was abolished by ARB as well as RAGE inhibitor. HMGB1 did not induce the accumulation of IP1, a downstream of Gαq signaling, in CHO cells expressing both AT1 and RAGE. Real-time imaging of cellular membrane revealed that RAGE induced endocytosis of LOX-1 that depends on the intact .β-arrestin pathway of AT1, and the phenomenon was not inhibited by ARB. Conclusions: RAGE ligands mediates cellular signaling via a physical interaction between RAGE and AT1. The activation of AT1 by RAGE ligands is distinct from that by angiotensin II in terms of selective G protein activation and the effect of ARB on G protein pathway but not on .β-arrestin pathway.
1 June 2011 in Journal Of Hypertension
24 August 2026 in The FASEB Journal